Optimal selection of antiemetics in children receiving cancer chemotherapy

Support Care Cancer. 1998 May;6(3):215-20. doi: 10.1007/s005200050156.


Only a few studies have been carried out specifically on the prevention of nausea and vomiting in children receiving chemotherapy. In these patients older antiemetic drugs such as metoclopramide and phenothiazines had moderate efficacy and induced significant side effects, especially marked sedation and extrapyramidal reactions. In comparative trials the 5-HT3 receptor antagonists have shown better efficacy and tolerability than chlorpromazine or metoclopramide combined with dexamethasone. The combination of a 5-HT3 receptor antagonist plus dexamethasone is superior to a 5-HT3 receptor antagonist alone and should be the standard antiemetic prophylaxis in all paediatric patients receiving highly or moderately emetogenic chemotherapy. The optimal dose and scheduling of these antiemetic drugs need to be studied, as well as the antiemetic efficacy, in the prevention of chemotherapy-induced delayed and anticipatory emesis in children.

Publication types

  • Comparative Study
  • Consensus Development Conference
  • Review

MeSH terms

  • Antiemetics / adverse effects
  • Antiemetics / therapeutic use*
  • Child
  • Dexamethasone / adverse effects
  • Dexamethasone / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Humans
  • Nausea / chemically induced
  • Nausea / drug therapy*
  • Neoplasms / drug therapy*
  • Neoplasms / physiopathology
  • Palliative Care*
  • Receptors, Serotonin / drug effects
  • Receptors, Serotonin / physiology
  • Receptors, Serotonin, 5-HT3
  • Serotonin Antagonists / adverse effects
  • Serotonin Antagonists / therapeutic use
  • Treatment Outcome
  • Vomiting / chemically induced
  • Vomiting / drug therapy*


  • Antiemetics
  • Receptors, Serotonin
  • Receptors, Serotonin, 5-HT3
  • Serotonin Antagonists
  • Dexamethasone